Cite
HARVARD Citation
De Castro, N. et al. (2021). Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial. Lancet infectious diseases. 21 (6), pp. 813-822. [Online].